Privately held Quark Pharmaceuticals Inc. stands to bank $680 million, including $10 million up front, under a deal granting Swiss pharma giant Novartis AG an option to obtain an exclusive worldwide license to develop and commercialize QPI-1002, an investigational p53 temporary inhibitor siRNA drug. (BioWorld Today) Read More
